BL
KERX

Bolton LP’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Bolton LP’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-179,900
Closed -$1.79M – 199
2015
Q2 		$1.79M Buy
+179,900
New +$1.93M 0.51% 46

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

Bolton LP's KERX Position: Q3 2015 in Review

Bolton LP sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2015, closing a stake of 179,900 shares — an estimated $1.79M sold.

Bolton LP first reported a position in KERX in Q2 2015 and held it in 1 quarter. The position peaked at $1.79M in Q2 2015. 138 funds tracked by Wall St. Rank hold KERX as of Q3 2015.

  • Bolton LP reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2015 after selling out during the quarter.
  • Bolton LP sold 179,900 Keryx Biopharmaceuticals Inc shares in Q3 2015, an estimated $1.79M.
  • Bolton LP first reported a position in Keryx Biopharmaceuticals Inc in Q2 2015 and held it in 1 quarter.
  • Bolton LP's Keryx Biopharmaceuticals Inc position peaked at $1.79M in Q2 2015.
  • 138 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2015.

Based on Bolton LP's 13F filing for Q3 2015, filed 16 Nov 2015.